Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
about
Drug delivery to the posterior segment of the eye for pharmacologic therapy.Influence of permeant lipophilicity on permeation across human scleraOcular pharmacokinetics of naringenin eye drops following topical administration to rabbitsAntiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.Transsclera Drug Delivery by Pulsed High-Intensity Focused Ultrasound (HIFU): An Ex Vivo Study.Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.Noninvasive routes of proteins and peptides drug delivery.A microparticle/hydrogel combination drug-delivery system for sustained release of retinoids.PPARgamma Agonists: Potential as Therapeutics for Neovascular RetinopathiesNovel approaches to retinal drug delivery.Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.Sustained transscleral drug delivery.Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug deliveryThe role of blood-ocular barrier transporters in retinal drug disposition: an overview.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier.Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.Challenges and solutions in topical ocular drug-delivery systems.Colloidal drug delivery system: amplify the ocular delivery.Advances in ocular drug delivery: emphasis on the posterior segment.Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.Assessment of trans-scleral iontophoresis delivery of lutein to the human retina.Safety and toxicity of nanomaterials for ocular drug delivery applications.Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.Recent perspectives on the delivery of biologics to back of the eye.Iontophoretic transport of charged macromolecules across human sclera.Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.Characterization of silicone pressure-sensitive adhesive episcleral implant for drug delivery.Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina.Electrically assisted delivery of macromolecules into the corneal epithelium.Principles of pharmacology in the eye.Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions.Diclofenac/biodegradable polymer micelles for ocular applications.A novel chemical delivery system comprising an ocular sustained release formulation of a 3alpha, 17alpha, 21-trihydroxy-5beta-pregnan-20-one-BIS-5-fluorouracil [correction of flourouracil] codrug.Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.Advances in the topical ocular drug deliveryPolymeric Materials in Ocular Drug Delivery Systems
P2860
Q30478379-B9179B59-DDA3-4C70-B7F7-6BE890641512Q34233208-C7670CAD-A060-4155-91F7-93704BB8C7F2Q34862764-4AB23DB2-CE37-4DDB-A9E4-33F0F940CF29Q34862792-80F5A022-86F7-43B2-A9BC-4CD84EFC218EQ35403847-A6514E21-0B99-440C-A7A9-4244A37734B0Q36024067-56B4D98A-BA7C-43F0-AC66-CCEB2CBB1789Q36029817-9E468251-489D-433C-8958-6702E4F2AA77Q36299877-43F35433-0CC3-4189-9799-F27347095D8AQ36676571-7B5E7D79-3886-4E75-A412-413F148A860FQ36903801-1AC9634E-5235-41CE-A2CA-E6345708DCC0Q36904857-C9D1E28C-0193-4A16-8666-D0D6EDA00BA2Q37039016-6C48661A-4CD6-4505-981C-50E97EF9BFBCQ37109083-EC1D0209-117D-4853-87E0-E242C83D89FEQ37396059-CEDA9148-157A-4C12-A8AB-D9EC165E8C29Q37741227-88CA83E5-D31D-4B06-A477-EE93FC2C3CF7Q37882685-827FA07A-C2F0-413A-A599-E07B653C610AQ37950461-3911BB56-17C4-438D-8200-33D20861D496Q38128390-9328C261-1CA1-45A4-AD11-9AB186D05C6DQ38177335-E693F6CC-0E05-44AB-94D3-EE3782239A75Q38217270-4F487769-3FD6-4E8B-8C58-AB32F74102CAQ38224320-0AEBD6B7-DB06-4E48-90D9-281FDE883973Q38227621-13D7126B-C4AC-420C-9EE6-9170EE16AE05Q38658699-A4873A8B-C881-453C-AFD8-E195A850DA46Q38793489-56275DE9-0DF1-4885-8B18-7D99845E4064Q38934604-8FC67763-F69C-488C-8C9E-F80A97C57241Q38940171-0808A1B6-30CF-445E-95D2-53DC8E81938CQ39623649-9EA66DEE-4D91-405A-A4B2-913580B6B024Q39826905-50781CAA-720E-4191-8B3C-7B4F0409533DQ40999904-C2C1EFE4-457C-4987-9BED-C3819F3A2F35Q42270577-60FA9753-617A-43F2-89FC-0EE3F2731155Q42914104-A9611A43-B015-4085-85E6-6586959BE44EQ45871474-57F69676-E6CB-4C72-891A-937EE4B1441BQ47143413-B1670DD5-C820-444A-989E-8017C8C53642Q47578401-D62DDA45-D5A6-497D-AC4B-64CFE2C61EF0Q48585439-0B55CC85-AE17-432C-B049-E50F9BD93EC8Q52673868-3EF2F6A8-27B1-4CB4-BCA0-CCD23DF9A7E7Q57381952-AD6C214A-4999-4181-B356-DC82774F72BAQ58436049-2043A44B-D4C3-401D-95B8-6ADD69249871
P2860
Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Recent progress in ocular drug ...... on transscleral iontophoresis.
@ast
Recent progress in ocular drug ...... on transscleral iontophoresis.
@en
type
label
Recent progress in ocular drug ...... on transscleral iontophoresis.
@ast
Recent progress in ocular drug ...... on transscleral iontophoresis.
@en
prefLabel
Recent progress in ocular drug ...... on transscleral iontophoresis.
@ast
Recent progress in ocular drug ...... on transscleral iontophoresis.
@en
P2093
P1476
Recent progress in ocular drug ...... on transscleral iontophoresis.
@en
P2093
Donna M Neumann
James M Hill
Marvin E Myles
P304
P356
10.1016/J.ADDR.2005.08.006
P407
P577
2005-11-28T00:00:00Z